Eroding norms over release of self-spreading viruses

Developing transmissible vaccines for animal infections

Intrinsically safe designs and a staged transparent development process will be essential.

Recombinant transmissible vaccines will be intrinsically contained despite the ability to superinfect

INTRODUCTION

Transmissible vaccines offer a novel approach to suppressing viruses in wildlife populations, with possible applications against viruses that infect humans as zoonoses - Lassa, Ebola, rabies. To ensure safety, current designs propose a recombinant vector platform in which the vector is isolated from the target wildlife population. Because using an endemic vector creates the potential for preexisting immunity to block vaccine transmission, these designs focus on vector viruses capable of superinfection, spreading throughout the host population following vaccination of few individuals.

AREAS COVERED

We present original theoretical arguments that, regardless of its R0 value, a recombinant vaccine using a superinfecting vector is not expected to expand its active infection coverage when released into a wildlife population that already carries the vector. However, if superinfection occurs at a high rate such that individuals are repeatedly infected throughout their lives, the immunity footprint in the population can be high despite a low incidence of active vaccine infections. Yet we provide reasons that the above expectation is optimistic.

EXPERT OPINION

High vaccine coverage will typically require repeated releases or release into a population lacking the vector, but careful attention to vector choice and vaccine engineering should also help improve transmissible vaccine utility.

Rabies in a postpandemic world: resilient reservoirs, redoubtable riposte, recurrent roadblocks, and resolute recidivism

Rabies is an ancient disease. Two centuries since Pasteur, fundamental progress occurred in virology, vaccinology, and diagnostics-and an understanding of pathobiology and epizootiology of rabies in testament to One Health-before common terminological coinage. Prevention, control, selective elimination, and even the unthinkable-occasional treatment-of this zoonosis dawned by the twenty-first century. However, in contrast to smallpox and rinderpest, eradication is a wishful misnomer applied to rabies, particularly post-COVID-19 pandemic. Reasons are minion. Polyhostality encompasses bats and mesocarnivores, but other mammals represent a diverse spectrum of potential hosts. While rabies virus is the classical member of the genus, other species of lyssaviruses also cause the disease. Some reservoirs remain cryptic. Although global, this viral encephalitis is untreatable and often ignored. As with other neglected diseases, laboratory-based surveillance falls short of the notifiable ideal, especially in lower- and middle-income countries. Calculation of actual burden defaults to a flux within broad health economic models. Competing priorities, lack of defined, long-term international donors, and shrinking local champions challenge human prophylaxis and mass dog vaccination toward targets of 2030 for even canine rabies impacts. For prevention, all licensed vaccines are delivered to the individual, whether parenteral or oral-essentially 'one and done'. Exploiting mammalian social behaviors, future 'spreadable vaccines' might increase the proportion of immunized hosts per unit effort. However, the release of replication-competent, genetically modified organisms selectively engineered to spread intentionally throughout a population raises significant biological, ethical, and regulatory issues in need of broader, transdisciplinary discourse. How this rather curious idea will evolve toward actual unconventional prevention, control, or elimination in the near term remains debatable. In the interim, more precise terminology and realistic expectations serve as the norm for diverse, collective constituents to maintain progress in the field.

Exploring the hurdles that remain for control of African swine fever in smallholder farming settings

To honour the 100 years anniversary of the first publication about African swine fever (ASF) a webinar with a particular focus on disease control in the smallholder sector was organized. This article is based on the webinar, summarizing the early history of ASF research, reflecting on the current global disease situation and bringing forward some suggestions that could contribute towards achieving control of ASF. The first description of ASF by R. Eustace Montgomery in 1921 laid the foundations for what we know about the disease today. Subsequent research confirmed its association with warthogs and soft ticks of the Ornithodoros moubata complex. During the latter half of the 21st century, exponential growth of pig production in Africa has led to a change in the ASF-epidemiology pattern. It is now dominated by a cycle involving domestic pigs and pork with virus spread driven by people. In 2007, a global ASF epidemic started, reaching large parts of Europe, Asia and the Americas. In Europe, this epidemic has primarily affected wild boar. In Asia, wild boar, smallholders and industrialized pig farms have been affected with impact on local, national and international pig value chains. Globally and historically, domestic pigs in smallholder settings are most frequently affected and the main driver of ASF virus transmission. Awaiting a safe and efficacious vaccine, we need to continue focus on other measures, such as biosecurity, for controlling the disease. However, smallholders face specific challenges linked to poverty and other structural factors in implementing biosecurity measures that can prevent spread. Improving biosecurity in the smallholder sector thus remains an important tool for preventing and controlling ASF. In this regard, interdisciplinary research can help to find new ways to promote safe practices, facilitate understanding and embrace smallholders' perspectives, engage stakeholders and adjust prevention and control policies to improve implementation.